UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 144

Sortiert nach

Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19

Biomedicine & pharmacotherapy, 2021-08, Vol.140, p.111785-111785, Article 111785

2021

Volltextzugriff (PDF)

Maintaining 'standards' for biosimilar monoclonal antibodies

Nature biotechnology, 2021-03, Vol.39 (3), p.276-280

2021

Volltextzugriff (PDF)

Biosimilars: what clinicians should know

Blood, 2012-12, Vol.120 (26), p.5111-5117

2012

Volltextzugriff (PDF)

The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring

Frontiers in immunology, 2021-04, Vol.12, p.636420-636420

2021

Volltextzugriff (PDF)

"Cytokine Storm" in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics

Journal of Immunology, 2007-09, Vol.179 (5), p.3325-3331

2007

Volltextzugriff (PDF)

Haematopoietic growth factors and their therapeutic use

Thrombosis and haemostasis, 2008-05, Vol.99 (5), p.863

2008

Volltextzugriff (PDF)

The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab

Biomolecules (Basel, Switzerland), 2021-10, Vol.11 (11), p.1610

2021

Volltextzugriff (PDF)

Impact of Formulation Choices on the Freeze-Drying of an Interleukin-6 Reference Material

Frontiers in molecular biosciences, 2022-07, Vol.9, p.868460-868460

2022

Volltextzugriff (PDF)

Surrogate CD16-expressing effector cell lines for determining the bioactivity of therapeutic monoclonal antibodies

Journal of pharmaceutical and biomedical analysis, 2017-09, Vol.143, p.188-198

2017

Volltextzugriff (PDF)

Editor's Highlight: Subvisible Aggregates of Immunogenic Proteins Promote a Th1-Type Response

Toxicological sciences, 2016-10, Vol.153 (2), p.258-270

2016

Volltextzugriff (PDF)

Detection of neutralizing antibodies to erythropoietin by inhibition of rHuEPO-stimulated EGR1 gene expression in the UT-7/EPO cell line

Journal of immunological methods, 2013-01, Vol.387 (1-2), p.191-198

2013

Volltextzugriff (PDF)

Harmonization and standardization of immunogenicity assessment of biotherapeutic products

Bioanalysis, 2019-09, Vol.11 (17), p.1593-1604

2019

Volltextzugriff (PDF)

Bioanalytical strategies in determining immunogenicity

Bioanalysis, 2019-09, Vol.11 (17), p.1535-1537

2019

Volltextzugriff (PDF)

WHO International Standards and reference preparations for cytokines and growth factors

Cytokine (Philadelphia, Pa.), 2019-11, Vol.123, p.154797-154797, Article 154797

2019

Volltextzugriff (PDF)

Unwanted Immunogenicity: Implications for Follow-on Biologicals

Therapeutic innovation & regulatory science, 2007-01, Vol.41 (1), p.1-9

2007

Volltextzugriff (PDF)

Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility

Biologicals, 2015-09, Vol.43 (5), p.298-306

2015

Volltextzugriff (PDF)

WHO guidelines on biosimilars: Toward improved access to safe and effective products

Annals of the New York Academy of Sciences, 2023-03, Vol.1521 (1), p.96-103

2023

Volltextzugriff (PDF)

Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy

Thrombosis research, 2018-03, Vol.163, p.105-116

2018

Volltextzugriff (PDF)

IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs

Journal of interferon & cytokine research, 2016-05, Vol.36 (5), p.302

2016

Volltextzugriff (PDF)

Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab

Cytokine (Philadelphia, Pa.), 2017-08, Vol.96, p.16-23

2017

Volltextzugriff (PDF)

WHO International Standards and Reference Preparations for Cytokines and Growth Factors

Journal of leukocyte biology, 2020-01, Vol.107 (1), p.159-160

2020

Volltextzugriff (PDF)

Biosimilars-why terminology matters

Nature biotechnology, 2011-08, Vol.29 (8), p.690-693

2011

Volltextzugriff (PDF)

Unwanted immunogenicity: lessons learned and future challenges

Bioanalysis, 2010-06, Vol.2 (6), p.1073-1084

2010

Volltextzugriff (PDF)

Intended use of Reference Products & WHO International Standards/Reference Reagents in the development of Similar Biological Products (Biosimilars)

Biologicals, 2011-09, Vol.39 (5), p.262-265

2011

Volltextzugriff (PDF)

Protein Engineering and HDX Identify Structural Regions of G‑CSF Critical to Its Stability and Aggregation

Molecular pharmaceutics, 2022-02, Vol.19 (2), p.616-629

2022

Volltextzugriff (PDF)

1 – 25 von 144

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(115)

Publikationsform

Sprache

Englisch
(144)
Japanisch
(7)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(114)
Life Sciences & Biomedicine
(109)
Humans
(79)
Biochemistry & Molecular Biology
(54)
Immunology
(38)
Biochemical Research Methods
(31)
Pharmacology & Pharmacy
(29)
Animals
(26)
World Health Organization
(20)
Immunogenicity
(19)
Biological And Medical Sciences
(18)
Cell Biology
(18)
Mice
(15)
Physical Sciences
(15)
Reference Standards
(15)
Biosimilar
(14)
Chemistry
(14)
Chemistry, Analytical
(13)
Hematology
(13)
Biotechnology & Applied Microbiology
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19

Maintaining 'standards' for biosimilar monoclonal antibodies

Biosimilars: what clinicians should know

The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring

"Cytokine Storm" in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics

Haematopoietic growth factors and their therapeutic use

The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab

Impact of Formulation Choices on the Freeze-Drying of an Interleukin-6 Reference Material

Surrogate CD16-expressing effector cell lines for determining the bioactivity of therapeutic monoclonal antibodies

Editor's Highlight: Subvisible Aggregates of Immunogenic Proteins Promote a Th1-Type Response

Detection of neutralizing antibodies to erythropoietin by inhibition of rHuEPO-stimulated EGR1 gene expression in the UT-7/EPO cell line

Harmonization and standardization of immunogenicity assessment of biotherapeutic products

Bioanalytical strategies in determining immunogenicity

WHO International Standards and reference preparations for cytokines and growth factors

Unwanted Immunogenicity: Implications for Follow-on Biologicals

Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility

WHO guidelines on biosimilars: Toward improved access to safe and effective products

Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy

IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs

Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab

WHO International Standards and Reference Preparations for Cytokines and Growth Factors

Biosimilars-why terminology matters

Unwanted immunogenicity: lessons learned and future challenges

Intended use of Reference Products & WHO International Standards/Reference Reagents in the development of Similar Biological Products (Biosimilars)

Protein Engineering and HDX Identify Structural Regions of G‑CSF Critical to Its Stability and Aggregation

Suchergebnisse filtern